silver fluoride
Silver Dihydrogen Citrate is a patented antimicrobial based on stabilized silver ion complex produced by a unique electrochemical process with silver and citric acid. Silver Dihydrogen Citrate provides a broad spectrum antimicrobial activity and is effective against unwanted bacteria, fungi, and viruses including pathogenic microorganisms. Its fast killing activity makes Silver Dihydrogen Citrate an effective antimicrobial for many applications. Silver has been used for centuries for its antimicrobial properties. In order for silver to be effective in killing microorganisms, it must be in an ionic form. Silver Dihydrogen Citrate is a complex of one silver ion weakly bound to one citrate ion having the molecular complex AgC6H7O7. Silver Dihydrogen Citrate provides a stabilized form of silver ion in an organic acid (citric acid). The bioavailability of the ions allows for Silver Dihydrogen Citrate to be rapidly effective against a broad spectrum of bacteria, viruses, and fungi. Silver ions are highly attracted to sulfur-containing thiol groups found in metabolic and structural proteins bound to the membrane surface. Silver Dihydrogen Citrate targets these critical proteins and destroys their structure. This disruption of the organisms’ membrane function and integrity lyses the membrane and the organism dies. — NCATS
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2017 (NCT03186261)
Timeline
Indications
Studied for
- Cariostatic Agents · Phase 4
- Dental Caries · Phase 4
- Dental Caries Susceptibility · Phase 4
- Dental Enamel Hypoplasia · Phase 2/Phase 3
- Dentin Sensitivity · Phase 2/Phase 3
- Fluorides, Topical · Phase 4
- Gastrointestinal Microbiome · Phase 3
- Hypersensitivity · Phase 2/Phase 3
- Tooth Abnormalities · Early Phase 1
- Tooth, Deciduous · Phase 3
Mechanism of action
- Unspecified targetOTHER
Other
Chemistry & pharmacology
SMILES
[Ag+]- Mol. weight
- 107.8682 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSilver fluoride ↗
- NCATS57N7B0K90A ↗
Also known as
- ag-f
- silver fluoride
- silver fluoride
- silver fluoride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06489093 | Early Phase 1 (Phase 1) | Jul 29, 2024 | Plovdiv Medical University |
| NCT06348849 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2024 | Alexandria University |
| NCT05221749 | Phase 3 | Mar 15, 2022 | Alexandria University |
| NCT04930458 | N/A | Aug 10, 2021 | University of Baghdad |
| NCT04887389 | Phase 4 | Jul 1, 2021 | Mansoura University |
| NCT04929509 | N/A | Dec 5, 2020 | Alexandria University |
| NCT04804423 | Phase 2/Phase 3 (Phase 3) | Jan 13, 2020 | SDI Limited, University of Greifswald |
| NCT03186261 | Phase 3 | Sep 1, 2017 | Cairo University |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexandria University | Academic/Hospital | 3 | 3 | 2 | 2020 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Mansoura University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Plovdiv Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| SDI Limited | For profit | 1 | 0 | 1 | 2020 |
| University of Baghdad | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Greifswald | Academic/Hospital | 1 | 1 | 1 | 2020 |